TGTX
HealthcareTG Therapeutics, Inc.
$29.90
+$0.62 (+2.12%)
Jan 5, 2026
Price History (1Y)
Analysis
TG Therapeutics, Inc. is a healthcare company operating in the biotechnology industry with a significant scale, boasting a market capitalization of $4.75B and 374 employees. The company's revenue has seen substantial growth, increasing by 92.8% year-over-year. Financially, TG Therapeutics appears to be profitable, with gross, operating, and profit margins all above 80%. The company's return on equity (ROE) is notably high at 112.0%, indicating strong profitability. On the other hand, the free cash flow is negative at $-94,664,496. The balance sheet indicates a substantial amount of debt ($254.54M), although this is offset by a relatively healthy current ratio of 3.83. The company's valuation metrics are mixed, with a P/E ratio (TTM) of 10.57 and forward P/E of 15.39, suggesting relatively low multiples compared to the industry average. However, the revenue growth rate has been exceptionally high at 92.8%, which may be driving these valuations. The dividend yield is not applicable, as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Visit website →Key Statistics
- Market Cap
- $4.75B
- P/E Ratio
- 10.57
- 52-Week High
- $46.48
- 52-Week Low
- $25.28
- Avg Volume
- 1.74M
- Beta
- 1.86
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 374